Adma Biologics reported $49.38M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Adma Biologics USD 49.38M 12.95M Dec/2025
Alnylam Pharmaceuticals USD 205.99M 19.57M Mar/2026
BioCryst Pharmaceuticals USD 245.84M 232.95M Dec/2025
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Novavax USD 17.53M 219.91M Dec/2025
Omeros USD -32.23M 23.81M Sep/2024
Takeda JPY -24.32B 127.96B Mar/2026